Evidence map›Paper›PMID 20218961›Full record

ReviewRecent patents on DNA & gene sequences2010

Modulation of ColE1-like plasmid replication for recombinant gene expression.

Manel Camps

Abstract readReview
In one paragraph

Review in Recent patents on DNA & gene sequences, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.

0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

49 citing papers in PubMed.

  1. Multi-gene Co-expression systems inSynthetic and systems biotechnology · 2026
    Review
  2. Article
  3. Article
  4. Antimicrobial agents and chemotherapy · 2025
    Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Molecular Characterization of a DNA Polymerase fromInternational journal of molecular sciences · 2022
    Article
  18. A plasmid system with tunable copy number.Nature communications · 2022
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Manel CampsDepartment of Microbiology and Environmental Toxicology, University of California at Santa Cruz, 1156 High Street, Santa Cruz, CA 95064, USA. mcamps@ucsc.edu

Funding

Creation of AlkB Mutants for Protection of Bone MarrowK08CA116429 · NCI · UNIVERSITY OF WASHINGTON · PI CAMPS, MANEL · 2006 to 2010
$657k
NCI NIH HHS K08 CA116429
6 · The paper itself

Abstract

ColE1-like plasmids constitute the most popular vectors for recombinant protein expression. ColE1 plasmid replication is tightly controlled by an antisense RNA mechanism that is highly dynamic, tuning plasmid metabolic burden to the physiological state of the host. Plasmid homeostasis is upset upon induction of recombinant protein expression because of non-physiological levels of expression and because of the frequently biased amino acid composition of recombinant proteins. Disregulation of plasmid replication is the main cause of collapse of plasmid-based expression systems because of a simultaneous increase in the metabolic burden (due to increased average copy number) and in the probability of generation of plasmid-free cells (due to increased copy number variation). Interference between regulatory elements of co-resident plasmids causes comparable effects on plasmid stability (plasmid incompatibility). Modulating plasmid copy number for recombinant gene expression aims at achieving a high gene dosage while preserving the stability of the expression system. Here I present strategies targeting plasmid replication for optimizing recombinant gene expression. Specifically, I review approaches aimed at modulating the antisense regulatory system (as well as their implications for plasmid incompatibility) and innovative strategies involving modulation of host factors, of R-loop formation, and of the timing of recombinant gene expression.

Indexed as

Bacterial ProteinsBacteriocin PlasmidsBase SequenceDNA ReplicationEscherichia coliMolecular Sequence DataMutationRecombinant ProteinsBacterial ProteinsRecombinant ProteinsROM protein, Bacteria

Identifiers

PMID20218961
PMCPMC2846101

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.